Bibliographic Details
| Title: |
Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. |
| Authors: |
Nicolatou-Galitis, Ourania, Kouri, Maria, Papadopoulou, Erofili, Vardas, Emmanouil, Galiti, Dimitra, Epstein, Joel B., Elad, Sharon, Campisi, Giuseppina, Tsoukalas, Nikolaos, Bektas-Kayhan, Kivanc, Tan, Winston, Body, Jean-Jacques, Migliorati, Cesar, Lalla, Rajesh V., for the MASCC Bone Study Group, MASCC Bone Study Group |
| Source: |
Supportive Care in Cancer; Feb2019, Vol. 27 Issue 2, p383-394, 12p |
| Subject Terms: |
OSTEONECROSIS, JAW necrosis, META-analysis, ANTINEOPLASTIC agents, PROTEIN-tyrosine kinase inhibitors, RAPAMYCIN, CANCER chemotherapy, CANCER patients |
| Abstract: |
Introduction: The reporting of osteonecrosis of the jaw (ONJ) related to anticancer agents without known antiresorptive properties (non-antiresorptives), such as antiangiogenics, tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapy is increasing.Objective: To review characteristics of ONJ in cancer patients receiving non-antiresorptives.Methods: A systematic review of the literature between 2009 and 2017 was conducted by the Bone Study Group of MASCC/ISOO.Results: Of 6249 articles reviewed and from personal communication, 42 ONJ cases related to non-antiresorptives were identified. No gender predilection was noted. Median age was 60 years and ONJ stage 2 was most common, with predilection for posterior mandible. Exposed bone, pain, and infection were common at diagnosis. In comparison to bone targeting agents (BTAs), radiology, histology, and management were similar, with medication often discontinued. Delayed diagnosis (median 8 weeks) was noted. Important differences included earlier time to ONJ onset (median 20 weeks), absence of trigger event (40%), and greater likelihood of healing and shorter healing time (median 8 weeks) as compared to BTA-related ONJ. Gastrointestinal cancers predominated, followed by renal cell carcinomas compared to breast, followed by prostate cancers in BTA-related ONJ, reflecting different medications.Conclusions: Data about non-antiresorptive-related ONJ is sparse. This type of ONJ may have better prognosis compared to the BTA-related ONJ, suggested by greater likelihood of healing and shorter healing time. However, the delay in diagnosis highlights the need for more education. This is the first attempt to characterize ONJ associated with different non-antiresorptives, including BRAF and immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR] |
|
Copyright of Supportive Care in Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
